Researchers evaluated the patient-specific factors that were associated with a greater risk of advanced disease at the time of melanoma diagnosis.

Immunotherapy among women with 2 types of genital tract melanoma, vulvar and vaginal melanoma, was associated with improved overall survival.

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

Adjuvant treatment with dabrafenib and trametinib may be more effective than observation or adjuvant treatment with a PD-1 inhibitor in patients with stage IIIA melanoma.

HonorHealth Research Institute recently treated the first patient in a 50-site international clinical trial that will test a ...

It accounts for only 1% of skin cancers, but it causes the most skin cancer ... Polsky and his colleagues focused on Stage ...

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a new study ...

Date & Time: April 28, 2-5 p.m. Summary: Building on findings presented at ASCO 2024, this study demonstrates that DecisionDx-Melanoma can identify early-stage CM ... (7.4% vs. 1.2%, p<0.001 ...

Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.